INFORMATION BY CANCER TYPE
Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.
Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.
Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.
The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.
Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.
After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.
The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.
Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.
The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.
As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Bladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of bladder cancer.
Gallbladder Cancer Treatment (PDQ®)
[ Patients ]
Expert-reviewed information summary about the treatment of gallbladder cancer.